Group | Variables |
Demographic features | Age at diagnosis, sex, race, and time to diagnosis |
Myositis subgroup | Polymyositis, dermatomyositis, or juvenile dermatomyositis |
Medication | Prednisone use, DMARD use, and number of total failed immunosuppressive agents at trial entry |
Clinical parameters | Physician’s Global Assessment, Muscle Disease Activity, Extramuscular Global Assessment, Constitutional Disease Activity, Cutaneous Disease Activity, Skeletal Disease Activity, Pulmonary Disease Activity, Patient’s/Parent’s Global Assessment, Manual Muscle Testing (MMT8), HAQ/C-HAQ Disability Index, and Overall Damage Score |
Laboratory parameters | Lymphocyte count, ALT levels, AST levels, aldolase levels, CPK levels, total IgM and IgG levels |
Autoantibody groups | Antisynthetase, anti-TIF-1γ,anti-SRP, anti-MJ, anti-Mi-2, other autoantibodies, no autoantibodies, or unspecified autoantibodies |
Gene Expression/ Cytokines/Chemokines | IFN gene score, IFN chemokine score, IFN-γ, IFN-α, IL-10, IL-12, IL-13, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-6, IL-17, IP-10, TNF-α, MIP-1α, MIP-1β, ITAC, MCP-1, MCP-2, MIG, and TNFR1 |